

Drug interactions with smoking

Many interactions between tobacco smoke and drugs have been identified. In most cases the cause of these drug interactions is the polycyclic aromatic hydrocarbons in tobacco smoke, not the nicotine.

Tobacco smoke may interact through either pharmacokinetic or pharmacodynamic mechanisms. People should be regularly monitored with regard to their smoking status and extent of cigarette consumption, and doses of relevant drugs adjusted accordingly.

Pharmacokinetic:

The polycyclic aromatic hydrocarbons in tobacco smoke stimulate hepatic enzymes cytochrome (CYP) P450 iso-enzymes (including 1A1, 1A2, 1B1, 2B6, 2E1). Induction of these enzymes (from smoking) may result in an increase in the metabolism of many drugs (that are substrates) and cause a subsequent decrease in plasma levels. 1A2 is the most clinically significant as many drugs are substrates of 1A2.

Smoking cessation results in the opposite effect – a decrease in metabolism and an increase in plasma concentrations. Dose adjustment is often required based on clinical presentation, side effect occurrence and monitoring of plasma levels.

Nicotine, including in nicotine replacement therapies (NRT) and e-cigarettes/vapes, does not affect the metabolism of other drugs.

Pharmacodynamic:

Nicotine can counter the pharmacological actions of certain drugs because it activates the sympathetic nervous system.

The amount of tobacco smoking needed to have this effect has yet to be established and therefore the assumption is that any person who smokes is susceptible. This assumption also extends to NRT and nicotine-containing e-cigarettes/vapes.

Disclaimer

The Drug interactions with smoking document (**Resource**) is a resource developed by Cancer Council Victoria with the assistance of Alfred Health and Pharmaceutical Society of Australia (PSA) which provides information to health professionals (you) for the sole purpose of guiding you to identify and manage drug interactions with smoking. It is intended for use as a guide of general nature only. The Resource is not exhaustive of subject matter including but not limited to side effects. It is not a substitute for you using your clinical judgment to determine individual medical needs. It is not intended to replace and should not be construed as medical advice. You must rely on your own skill and care with respect to the appropriateness of your use of the Resource.

While Cancer Council Victoria, Alfred Health and PSA endeavour to ensure the accuracy of the information contained in the Resource, no statement, representation, warranty or guarantee is given about:

- the information being accurate, complete, up-to-date, reliable or fit for a particular purpose; and
- the availability of the information in or accessible through the web-based Resource.

Cancer Council Victoria, Alfred Health and PSA assume no liability for any consequences of relying on such information. All information within the Resource must be considered and utilised in conjunction with local hospital protocols and guidelines.









The information contained in the Resource is being provided to you on the condition that, and by using this information you accept that:











- You are responsible for all risks, losses, damages, costs, and other consequences resulting directly or indirectly from using the Resource; and
- to the maximum extent permitted by law, Cancer Council Victoria, Alfred Health and PSA are not liable (including for negligence) for any direct or indirect expense, loss, damage, claim, cost, or other compensation incurred by you or any other person resulting from any use or access of the Resource.

Your access to and use of the Resource does not grant or transfer to you any rights in relation to the Resource.

The Resource (in part or as a whole) cannot be reproduced, published, communicated, or adapted without the prior written consent of Cancer Council Victoria. Any request or enquiry in relation to the Resource should be addressed to contact@quitcentre.org.au.



Drug	Nature of interaction with smoking Pharmacokinetic (PK) Pharmacodynamic (PD)	Action upon cessation of smoking	Clinical significance
Caffeine	PK: Increased clearance and decreased plasma concentrations.	Advise to reduce caffeine by half. Monitor for increased side effects (e.g. headache, jitteriness, restlessness, insomnia).	 High
Clozapine	PK: Increased clearance and decreased plasma concentrations.	Monitor trough plasma concentrations (if possible before stopping smoking and for two weeks after or sooner if side effects develop). Monitor for increased side effects. Dose reductions may be required if clinically appropriate. Seek specialist advice from treating mental health practitioner.	 High
Erlotinib	PK: Increased clearance and decreased plasma concentrations (around two-fold).	Revert to standard dosing if a patient stops smoking. Seek specialist advice. Nb. People who smoke should be advised to stop before therapy is initiated.	 High
Olanzapine	PK: Increased clearance and decreased plasma concentrations.	Monitor for increased side effects (e.g. dizziness, sedation, hypotension). Dose reductions may be required if clinically appropriate. Seek specialist advice from treating mental health practitioner.	 High
Pirfenidone	PK: Decreased AUC and decreased Cmax.	Seek specialist advice. Nb. People who smoke should be advised to stop before therapy is initiated.	 High
Riociguat	PK: Increased clearance and decreased plasma concentrations.	Monitor for increased side effects (e.g. dizziness, headache, nausea, diarrhoea). Dose reductions may be required if clinically appropriate. Nb. People who smoke should be advised to stop before therapy is initiated.	 High
Theophylline	PK: Increased clearance and decreased half-life.	Monitor theophylline levels and reduce dose if clinically appropriate. Advise patient to monitor for signs of toxicity (e.g. palpitations, vomiting, nausea). Nb. It may take several weeks for enzyme induction to dissipate.	 High
Agomelatine	PK: Increased clearance and decreased plasma concentrations. Nb. The interaction may be more profound in people smoking > 15 cigarettes per day.	Monitor for side effects (e.g. dizziness, sedation, nausea). Reduce dose if clinically appropriate. Seek specialist advice.	 Moderate

Drug	Nature of interaction with smoking Pharmacokinetic (PK) Pharmacodynamic (PD)	Action upon cessation of smoking	Clinical significance
Chlorpromazine	PK: Increased clearance and decreased plasma concentrations.	Monitor for increased side effects (e.g. dizziness, sedation, extrapyramidal side effects). Reduce dose if clinically appropriate.	 Moderate
Cinacalcet	PK: Increased clearance (around 38%) and decreased plasma concentrations.	Seek specialist advice.	 Moderate
Flecainide	PK: Increased clearance and decreased plasma concentrations.	Monitor for side effects (e.g. dizziness, shortness of breath, arrhythmias). Reduce dose if clinically appropriate.	 Moderate
Fluvoxamine	PK: Increased clearance and decreased plasma concentrations.	Monitor for side effects (e.g. nausea, tremor, nystagmus). Reduce dose if clinically appropriate.	 Moderate
Insulin	Unclear: Possible decrease in insulin absorption secondary to peripheral vasoconstriction. Smoking may also increase insulin resistance.	Advise patient to monitor for signs of hypoglycaemia and to test their BGLs more frequently. Reduce dose if clinically appropriate.	 Moderate
Irinotecan	PK: Increased clearance and decreased plasma concentrations of active metabolite.	Seek specialist advice. Dosing should be closely monitored.	 Moderate
Methadone	PK: Increased clearance and decreased plasma concentrations.	Monitor closely and adjust dose if clinically appropriate. Seek specialist advice.	 Moderate
Mexiletine	PK: Increased clearance and decreased plasma concentrations.	Monitor for side effects (e.g. nausea, tremor, hypotension). Reduce dose if clinically appropriate. Seek specialist advice.	 Moderate
Riluzole	PK: Increased clearance (20%) and decreased plasma concentrations.	Monitor for side effects (e.g. drowsiness, headache, dizziness). Seek specialist advice.	 Moderate
Ropinirole	PK: Decreased AUC and decreased Cmax.	Monitor for increased side effects (e.g. nausea, dizziness). Reduce dose if clinically appropriate.	 Moderate

Drug	Nature of interaction with smoking Pharmacokinetic (PK) Pharmacodynamic (PD)	Action upon cessation of smoking	Clinical significance
Warfarin	PK: Increased clearance and decreased plasma concentrations.	Monitor for side effects and increased bleeding. Monitor INR closely. Reduce dose if clinically appropriate.	 Moderate
Benzodiazepines	Likely PD: CNS stimulation by smoking. Nb. Results from PK studies are mixed.	Monitor for side effects (enhanced effect of benzodiazepines). Reduce dose if clinically appropriate.	 Low
Betablockers	PD: CNS stimulation by smoking opposes the beneficial effects of beta blockers on blood pressure and heart rate.	Monitor for increased response (e.g. blood pressure, treatment response for angina). Reduce dose if clinically appropriate.	 Low
Clopidogrel	PK: Data is conflicting. Possible higher antiplatelet effect in people who smoke.	Smoking cessation should still be recommended.	 Low
Duloxetine, imipramine	PK: Decreased plasma concentrations.	Monitor for increased side effects. Reduce dose if clinically appropriate.	 Low
Haloperidol	PK: Increased clearance and decreased plasma concentrations.	Monitor for increased side effects (e.g. drowsiness, extrapyramidal side effects). Reduce dose if clinically appropriate.	 Low
Heparin	Unclear: Increased clearance and decreased half-life observed. Smoking has prothrombotic effects.	Monitor for side effects and adjust dose based on APTT as appropriate.	 Low
Nintedanib	PK: Decreased exposure in people who smoke.	No dosage adjustment required. People should not smoke during use.	 Low